MedVasc

Based in Sweden, MedVasc AB develops innovative medical technologies, focusing on the Solutio catheter, which enhances local anesthesia delivery for medical procedures, ensuring improved patient comfort and procedural efficiency. MedVasc AB, founded in 2013 and headquartered in Lund, Sweden, specializes in the development of medical devices. The company has successfully completed two funding rounds, with the most recent deal occurring on April 15, 2025, where it raised EUR 917,000 from Life Science Invest among others. This funding will assist in product development and regulatory approval preparation.

The company has not undergone any significant pivots or changes in its business model since inception. MedVasc AB specializes in innovative medical devices, particularly the Solutio catheter, which revolutionizes local anesthesia administration by delivering anesthetic directly within the vein. This approach significantly reduces patient discomfort during thermal ablation procedures for varicose veins. Following successful clinical trials, the Solutio catheter is set to enter the U.

S. market as it navigates the FDA 510(k) regulatory process, targeting healthcare professionals and institutions engaged in varicose vein treatments globally. MedVasc AB's revenue model revolves around the commercialization of its Solutio catheter, primarily engaging with healthcare providers and hospitals specializing in vascular treatments. The company operates on a business-to-business (B2B) basis, ensuring direct sales to medical facilities.

The pricing strategy accommodates bulk orders in alignment with institutional purchasing practices. As regulatory approval is achieved and market access is gained, the company anticipates revenue from direct sales and potential partnerships with medical device distributors, aiming to solidify its presence in the global medical device market. In April 2025, MedVasc AB secured EUR 917,000 in venture funding, which will be used for product development and preparation for regulatory approvals. The company plans to launch the Solutio catheter in additional markets, focusing on expanding its reach into the U.

S. healthcare sector while also exploring opportunities in other international regions. This funding will be instrumental in supporting these initiatives as the company seeks to enhance its product offerings and strengthen relationships with healthcare providers.